Hostname: page-component-89b8bd64d-shngb Total loading time: 0 Render date: 2026-05-07T15:09:18.236Z Has data issue: false hasContentIssue false

Addenbrooke's cognitive examination III: diagnostic utility for mild cognitive impairment and dementia and correlation with standardized neuropsychological tests

Published online by Cambridge University Press:  29 September 2016

Jordi A. Matias-Guiu*
Affiliation:
Department of Neurology, Hospital Clínico San Carlos, San Carlos Institute for Health Research (IdISSC), Universidad Complutense de Madrid, Madrid, Spain
Ana Cortés-Martínez
Affiliation:
Department of Neurology, Hospital Clínico San Carlos, San Carlos Institute for Health Research (IdISSC), Universidad Complutense de Madrid, Madrid, Spain
Maria Valles-Salgado
Affiliation:
Department of Neurology, Hospital Clínico San Carlos, San Carlos Institute for Health Research (IdISSC), Universidad Complutense de Madrid, Madrid, Spain
Teresa Rognoni
Affiliation:
Department of Neurology, Hospital Clínico San Carlos, San Carlos Institute for Health Research (IdISSC), Universidad Complutense de Madrid, Madrid, Spain
Marta Fernández-Matarrubia
Affiliation:
Department of Neurology, Hospital Clínico San Carlos, San Carlos Institute for Health Research (IdISSC), Universidad Complutense de Madrid, Madrid, Spain
Teresa Moreno-Ramos
Affiliation:
Department of Neurology, Hospital Clínico San Carlos, San Carlos Institute for Health Research (IdISSC), Universidad Complutense de Madrid, Madrid, Spain
Jorge Matías-Guiu
Affiliation:
Department of Neurology, Hospital Clínico San Carlos, San Carlos Institute for Health Research (IdISSC), Universidad Complutense de Madrid, Madrid, Spain
*
Correspondence should be addressed to: Jordi A. Matias-Guiu, Department of Neurology, Hospital Clinico San Carlos, San Carlos Institute for Health Research (IdISSC), Universidad Complutense, Calle Profesor Martin Lagos S/N, 28040, Madrid, Spain. Phone: +34676933312, +34913303511. Email: jordimatiasguiu@hotmail.com, jordi.matias-guiu@salud.madrid.org.
Get access

Abstract

Background:

Addenbrooke's Cognitive Examination III (ACE-III) is a screening test that was recently validated for diagnosing dementia. Since it assesses attention, language, memory, fluency, and visuospatial function separately, it may also be useful for general neuropsychological assessments. The aim of this study was to analyze the tool's ability to detect early stages of Alzheimer's disease and to examine the correlation between ACE-III scores and scores on standardized neuropsychological tests.

Methods:

Our study included 200 participants categorized as follows: 25 healthy controls, 48 individuals with subjective memory complaints, 47 patients with amnestic mild cognitive impairment and 47 mild Alzheimer's disease, and 33 patients with other neurodegenerative diseases.

Results:

The ACE-III memory and language domains were highly correlated with the neuropsychological tests specific to those domains (Pearson correlation coefficient of 0.806 for total delayed recall on the Free and Cued Selective Reminding Test vs. 0.744 on the Boston Naming Test). ACE-III scores discriminated between controls and patients with amnestic mild cognitive impairment (AUC: 0.906), and between controls and patients with mild Alzheimer's disease (AUC: 0.978).

Conclusion:

Our results suggest that ACE-III is a useful neuropsychological test for assessing the cognitive domains of attention, language, memory, and visuospatial function. It also enables detection of Alzheimer's disease in early stages.

Information

Type
Research Article
Copyright
Copyright © International Psychogeriatric Association 2016 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

Supplementary material: File

Matias-Guiu supplementary material

Table S1

Download Matias-Guiu supplementary material(File)
File 128.4 KB